First AD

Second AD

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

Video content above is prompted by the following questions:

Please comment on the trial led to the approval of use for asparaginase erwinia chrysanthemi in AYA ALL.

How does for asparaginase erwinia chrysanthemi work?

What are your thoughts on the key efficacy outcomes?

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Inside the Clinic: Treating AYA ALL